| Literature DB >> 31410221 |
Lei Xu1,2, Pengfei Yang1,2,3, Wenjie Liang4, Weihai Liu4, Weigen Wang5, Chen Luo1,2, Jing Wang1,2, Zhiyi Peng4, Lei Xing6, Mi Huang7, Shusen Zheng8, Tianye Niu1,2,9.
Abstract
Purpose: Accurate lymph node (LN) status evaluation for intrahepatic cholangiocarcinoma (ICC) patients is essential for surgical planning. This study aimed to develop and validate a prediction model for preoperative LN status evaluation in ICC patients. Methods and Materials: A group of 106 ICC patients, who were diagnosed between April 2011 and February 2016, was used for prediction model training. Image features were extracted from T1-weighted contrast-enhanced MR images. A support vector machine (SVM) model was built by using the most LN status-related features, which were selected using the maximum relevance minimum redundancy (mRMR) algorithm. The mRMR method ranked each feature according to its relevance to the LN status and redundancy with other features. An SVM score was calculated for each patient to reflect the LN metastasis (LNM) probability from the SVM model. Finally, a combination nomogram was constructed by incorporating the SVM score and clinical features. An independent group of 42 patients who were diagnosed from March 2016 to November 2017 was used to validate the prediction models. The model performances were evaluated on discrimination, calibration, and clinical utility.Entities:
Keywords: Radiomics; intrahepatic cholangiocarcinoma; lymph node metastasis
Mesh:
Year: 2019 PMID: 31410221 PMCID: PMC6691572 DOI: 10.7150/thno.34149
Source DB: PubMed Journal: Theranostics ISSN: 1838-7640 Impact factor: 11.556
Univariate analysis and correlation test for radiomics features used in the SVM model for the training group
| Radiomics features | Training group (n=106) | Correlation coefficient | |||
|---|---|---|---|---|---|
| LNM | non-LNM | ||||
| HLH_GLCM_maxpr | 0.2854 (0.2651 to 0.3175) | 0.2665(0.2425 to 0.2805) | 0.0164 | 0.2343 | 0.0156 |
| LLH_GLCM_sosvh | 1.0462 (0.9128 to 1.1260) | 1.1206 (0.9829 to 1.1929) | 0.0963 | -0.1623 | 0.0965 |
| HLL_GLCM_corrm | -0.0178 (-0.0212 to -0.0152) | -0.0146 (-0.0175 to -0.0115) | 0.0629 | -0.1815 | 0.0626 |
| LLL_GLCM_denth | 2.7902 (2.7389 to 2.8908) | 2.9404 (2.8816 to 2.9863) | 0.0014 | -0.3112 | 0.0012 |
| HLL_GLSZM_LGZE | 0.0013 (0.0010 to 0.0014) | 0.0018 (0.0014 to 0.0023) | 0.0028 | 0.2920 | 0.0024 |
Note: The univariate analysis for radiomics features was applied by using the Mann-Whitney U test.
The correlation between radiomics features and the LN status was applied by using the Spearman rank correlation test.
All features were reported as median and 95% confidence interval.
Figure 2The ROC curves of the SVM model in the training group (A) and the validation group (B). The scatter plots of the SVM scores in the training group (C) and the validation group (D). The blue markers indicate patients with synchronous LNM; the red markers indicate patients with non-LNM. The black horizontal line presents the threshold. Patients with SVM scores higher than 0. 4915 are classified as LNM; patients with scores lower than 0. 4915 are classified as non-LNM.
Figure 3The combination nomogram, combining SVM score, CA 19-9 level, and the MR-reported LNM factor.
Figure 4The ROC curves of the combination nomogram in the training group (A) and the validation group (B). The scatter plots for the nomogram score in the training group (C) and the validation group (D). The blue markers indicate patients with synchronous LNM; the red markers indicate patients with non-LNM. The black horizontal line presents the threshold. Patients with nomogram scores higher than -0.8270 are classified as LNM; patients with scores lower than -0.8270 are classified as non-LNM.
Figure 5The calibration curves of the combination nomogram in the training group (A) and the validation group (B). Vertical axis: the actual probability of LNM probability; horizontal axis: the nomogram predicted LNM probability; the diagonal line: the perfect prediction with predicted LNM probabilities equal to the actual LNM probabilities. The decision curves of the SVM model and the combination nomogram in the training group (C) and the validation group (D). Vertical axis: the net benefit; horizontal axis: the threshold probability at a range of 0.0 to 1.0. The red and black dotted lines represent the decision curve of the combination nomogram and the SVM model, respectively. The gray line represents the decision curve of the assumption that all patients suffer from LNM; the black line represents the decision curve of the assumption that no patients suffer from LNM.
Performances of the SVM model, combination nomogram and MR-reported LNM
| Models | Training group | Validation group | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accuracy | AUC (95%CI) | Sensitivity | Specificity | S. E. | Accuracy | AUC (95%CI) | Sensitivity | Specificity | S. E. | ||
| SVM score | 73.58% | 0.788 (0.698 - 0.862) | 65.96% | 79.66% | 0.0441 | 69.05% | 0.787 (0.634 - 0.898) | 52.63% | 91.30% | 0.0695 | |
| Combination model | 72.64% | 0.842 (0.758 - 0.906) | 89.36% | 57.63% | 0.0387 | 78.57% | 0.870 (0.730 - 0.953) | 89.47% | 69.57% | 0.0540 | |
| MR-reported LNM | 66.04% | 0.658 (0.560 - 0.748) | 63.83% | 67.80% | 0.0469 | 66.67% | 0.673 (0.511 - 0.809) | 73.68% | 60.87% | 0.0735 | |
Note: SVM, support vector machine; S.E., standard error; CI, confidence interval.
Figure 6ROC curves for the SVM model and combination nomogram in the overall group.
Patients and preoperative clinical feature
| Clinical features | Training group (n=106) | Validation group (n=42) | ||||
|---|---|---|---|---|---|---|
| LNM | non-LNM | LNM | non-LNM | |||
| Age (Mean± SD) | 58.02 ± 10.54 | 60.05 ± 8.52 | 0.2755 | 55.93 ± 15.25 | 60.34 ± 7.17 | 0.4662 |
| Range | (35, 77) | (39, 86) | (40, 80) | (43, 76) | ||
| Gender | 0.8450 | 0.5547 | ||||
| Male | 23 | 30 | 5 | 8 | ||
| Female | 24 | 29 | 14 | 15 | ||
| Primary hepatic lobe site | 0.6683 | 0.2479 | ||||
| Left | 30 | 40 | 14 | 13 | ||
| Right | 17 | 19 | 5 | 10 | ||
| Number of the primary tumors | 0.0013 | 0.1536 | ||||
| Single | 30 | 53 | 12 | 19 | ||
| Multiple | 17 | 6 | 7 | 4 | ||
| Hepatitis | 0.7065 | 0.6179 | ||||
| Without | 35 | 42 | 15 | 24 | ||
| With | 12 | 17 | 4 | 9 | ||
| Cirrhosis | 0.4274 | 0.6673 | ||||
| Without | 46 | 56 | 18 | 21 | ||
| With | 1 | 3 | 1 | 2 | ||
| Cholelithiasis | 0.2506 | 0.7030 | ||||
| Without | 38 | 42 | 15 | 17 | ||
| With | 9 | 17 | 4 | 6 | ||
| CA19-9 | 0.0086 | 0.0339 | ||||
| Normal | 10 | 27 | 7 | 16 | ||
| Abnormal | 37 | 32 | 12 | 7 | ||
| CEA | 0.0674 | 0.0143 | ||||
| Normal | 29 | 46 | 10 | 20 | ||
| Abnormal | 18 | 13 | 9 | 3 | ||
| MR-reported LNM | 0.0012 | 0.0251 | ||||
| Negative | 17 | 40 | 5 | 14 | ||
| Positive | 30 | 19 | 14 | 9 | ||
Note: LNM, lymph node metastasis; CA19-9, serum carbohydrate antigen 19-9; CEA, serum carcinoembryonic antigen; SD, standard deviation.